ArticleMediators of inflammation2026
Investigating the Role of TNFSF12 in Thyroid Cancer Progression via Single-Cell RNA Sequencing and Integrated Multiomics Analyses.
Article in Mediators of inflammation, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Investigating the Role of TNFSF12 in Thyroid Cancer Progression via Single-Cell RNA Sequencing and Integrated Multiomics Analyses.Mediators of inflammation · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThyroid carcinoma is characterized by significant heterogeneity and immune evasion, in which myeloid cells play a pivotal role in tumor microenvironment (TME) remodeling. However, the key regulatory genes and their underlying mechanisms are not yet fully elucidated.
objectiveThis study aims to identify and validate critical myeloid-derived genes involved in driving thyroid cancer progression by employing an integrated multiomics approach.
methodsWe performed single-cell RNA sequencing (scRNA-seq) on thyroid cancer tissues, integrated with High-dimensional weighted gene co-expression network analysis (hdWGCNA) for coexpression module identification, Mendelian randomization (MR) for causal inference, and functional validation assays in thyroid carcinoma cell lines including qPCR, CCK-8, colony formation, and transwell assays. Microbial correlation analysis and molecular docking were additionally conducted to explore potential interactions.
resultsWe identified a tumor-specific myeloid subpopulation (C5) and a disease-associated coexpression module harboring three hub genes: MERTK, MSR1, and TNFSF12. MR analysis confirmed MERTK and MSR1 as genetic risk factors for thyroid cancer progression, whereas TNFSF12 exhibited protective effects. Functional experiments demonstrated that TNFSF12 enhances proliferative, invasive, and migratory capacities in thyroid cancer cells. Furthermore, MSR1 and MERTK were found to be significantly correlated with specific intratumoral microbiota and associated with BRAF mutation and response to immunotherapy.
conclusionOur study reveals a myeloid-centered regulatory network in thyroid cancer and highlights TNFSF12 as a context-dependent oncogene, offering novel insights into targeted therapy and immunotherapeutic strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.